GT Biopharma (GTBP) Appoints Andrew Ritter to its Board

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of Andrew Ritter to its Board of Directors. Mr. Ritter will be replacing current board member Dr. Rajesh Shrotriya, who is resigning from his position.

“We are very pleased to welcome Andrew to the Board of Directors. Andrew is a deeply talented biotech executive with a proven track record of building and scaling healthcare companies and leading multiple successful exits,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “His insight and perspective will be invaluable as our NK engagers advance through clinical trials and GT Biopharma continues to evolve as a company.”

Mr. Ritter has over two decades of leadership experience in biotechnology and healthcare technology. He currently serves as Chief Executive Officer of Cairns Health, an innovator in AI-powered remote care solutions supporting Home and Senior Care. Previously, Mr. Ritter was the Chief Executive Officer of Docbot, an AI-driven MedTech company, for which he successfully led its exit to a strategic. He also founded and served as Chief Executive Officer of Ritter Pharmaceuticals for nearly 17 years, where he guided the company from Phase I through Phase III clinical trials. Under his leadership, Ritter Pharmaceuticals became one of the first microbiome-based biotech companies to go public on NASDAQ and later successfully merged with Qualigen Therapeutics. In addition, he was a founding board member of Myosin Therapeutics, a biotech spin-out from Scripps Research, where he helped secure the company’s initial financing and supported its early growth over a four-year board tenure. Mr. Ritter earned a B.A. in political science at the University of Southern California and a Master of Business Administration at the Wharton School, University of Pennsylvania.

You May Also Be Interested In

• NNN REIT adds two directors amid board succession planning
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026
• Wendy's U.S. president to resign, company to create COO role